Hypofractionated radiotherapy for glioblastoma: Strategy for poor-risk patients or hope for the future?

British Journal of Radiology

Volumn 85, Issue 1017, 2012, Pages

  Hingorani, Mohan ^a   Colley, W P ^a   Dixit, S ^a   Beavis, A M ^a,b,c  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

CANCER RADIOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; GLIOBLASTOMA; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; KARNOFSKY PERFORMANCE STATUS; OVERALL SURVIVAL; PATIENT SAFETY; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION NECROSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

BRAIN NEOPLASMS; DOSE FRACTIONATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; PREVALENCE; PROGNOSIS; RADIOTHERAPY, CONFORMAL; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84866063199     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/83827377     Document Type: Review

References (59)

1. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333-43.
2. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31.
3. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991;64:769-74.
4. Budach W, Gioioso D, Taghian A, Stuschke M, Suit HD. Repopulation capacity during fractionated irradiation of squamous cell carcinomas and glioblastomas in vitro. Int J Radiat Oncol Biol Phys 1997;39:743-50.
5. Loeffier JS, Alexander E 3rd, Shea WM. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992;10:1379-85.
6. Burnet NG, Jena R, Jefferies SJ, Stenning SP, Kirkby NF. Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment. Clin Oncol (R Coll Radiol) 2006;18:93-103.
7. Perez, LA, Dombkowski D, Efird J, Preffer, F, Suit, HD. Cell proliferation kinetics in human tumor xenografts measured with iododeoxyuridine labeling and flow cytometry: a study of heterogeneity and a comparison between different methods of calculation and other proliferation measurements. Cancer Res 1995;55:392-8.
8. Jones B, Sanghera P. Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma. Int J Radiat Oncol Biol Phys 2007;68:441-8.
9. Taghian A, Suit H, Pardo F, Gioioso D, Tomkinson K, DuBois W, et al. In vitro intrinsic radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1992;23:55-62.
10. Do V, Gebski V, Barton MB. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol 2000;57:131-6.
11. Hlatky L, Olesiak M, Hahnfeldt P. Measurement of potential doubling time for human tumor xenografts using the cytokinesis-block method. Cancer Res 1996;56:1660-3.
12. Plowman PN, Pinkerton CR, eds. Paediatric oncology: clinical practice and controversies. London, UK: Chapman and Hall; 1992.
13. Haas-Kogan DA, Yount G, Haas M, Levi D, Kogan SS, Hu L, et al. p53-dependent G1 arrest and p53 independent apoptosis influence the radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys 1996;36:95-103.
14. Sarvi M, Sappelsa L, Blazek ER. Glioblastoma cell line killing by fractionated radiation does not follow the assumption of equal effect per fraction. Int J Radiat Oncol Biol Phys 2002;54:53-4.
15. Dionysiou DD, Stamatakos GS, Gintides D, Uzunoglu N, Kyriaki K. Critical parameters determining standard radiotherapy treatment outcome for glioblastoma multiforme: a computer simulation. Open Biomed Eng J 2008;2:43-51.
16. Thomas R, James N, Guerrero D, Ashley S, Gregor A, Brada M. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol 1994;33:113-16.
17. McAleese JJ, Stenning SP, Ashley S, Traish D, Hines F, Sardell S, et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched pair survival analysis with MRC controls. Radiother Oncol 2003;67:177-82.
18. Chang EL, Yi W, Allen PK, Levin VA, Sawaya RE, Maor MH. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 2003;56:519-28.
19. Lutterbach J, Ostertag C. What is the appropriate radiotherapy protocol for older patients with newly diagnosed glioblastoma? J Clin Oncol 2005;23:2869-70.
20. Kleinberg L, Slick T, Enger C, Grossman S, Bram H, Wharram MD Jr. Short course radiotherapy is an appropriate option for most malignant glioma patients. Int J Radiat Oncol Biol Phys 1997;38:31-6.
21. Slotman BJ, Kralendonk JH, van Alphen HA, Kamphorst W, Karim AB. Hypofractionated radiation therapy in patients with glioblastoma multiforme: Results of treatment and impact of prognostic factors. Int J Radiat Oncol Biol Phys 1996;34:895-8.
22. Ford JM, Stenning SP, Boote DJ, Counsell R, Falk Sj, Flavin A, et al. A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol) 1997;9:20-4.
23. Arslan M, Karadeniz AN, Aksu G, Güveli M, Fayda M, Doǧan AK, et al. Postoperative hypofractionated radiotherapy in glioblastoma multiforme. J BUON 2006;11:39-42.
24. Sayin MY, Kaya B, Bakkal BH, Altundag K, Altundag MB. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas. Med Oncol 2007;24:379-83.
25. Glinski B. Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas: a preliminary report on a randomized trial. J Neurooncol 1993;16:167-72.
26. Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22:1583-8.
27. Hulshof MC, Schimmel EC, Andries Bosch D, Gonzales D. Hypofractionation in glioblastoma multiforme. Radiother Oncol 2000;54:143-8.
28. Floyd NS, Woo SY, Teh BS, Prado C, Mai WY, Trask T, et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2004;58:721-6.
29. Sultanem K, Patrocinio H, Lambert C, Corns R, Leblanc R, Parker W, et al. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys 2004;58:247-52.
30. Iuchi T, Hatano K, Narita Y, Kodama T, Yamaki T, Osato K. Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 2006;64:1317-24.
31. Monjazeb AM, Ayala D, Jensen C, Case LD, Bourland JD, Ellis TL, et al. A Phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012;82:743-8.
32. Minniti G, De Sanctis V, Muni R, Rasio D, Lanzetta G, Bozzao A, et al. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 2009;91:95-100.
33. Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-Demasters BK, et al. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;81:1066-74.
34. Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, et al. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 2009;73:473-8.
35. Terasaki M, Eto T, Nakashima S, Okada Y, Ogo E, Sugita Y, et al. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. J Neurooncol 2011;102:247-53.
36. Morganti AG, Balducci M, Salvati M, Esposito V, Romanelli P, Ferro M, et al. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. Int J Radiat Oncol Biol Phys 2010;77:92-7.
37. Nakagawa K, Aoki Y, Fujimaki T, Tago M, Terahara A, Karasawa K, et al. High-dose conformal radiotherapy in uenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998;40:1141-9.
38. Chan JL, Lee SW, Frass BA. Survival and failure patterns of high grade glioma after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20:1635-42.
39. Laperriere NJ, Leung PM, Mckenzie S, Milosevic M, Wong S, Glen J, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998;41:1005-11.
40. Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, et al. The Brain Tumor Cooperative Group, NIH trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiotherapy, and carmustine. Neurosurgery 2002;51:343-55.
41. Souhami L, Scott C, Brachman D. Randomized prospective comparison of stereotactic radiosurgery (SRS) followed by conventional radiotherapy (RT) with BCNU to RT with BCNU alone for selected patients with supratentorial glioblastoma multiforme (GBM). Int J Radiat Oncol Biol Phys 2002;54:94-5.
42. Nelson DF, Curran WJ, Scott C, Nelson JS, Weinstein AS, Ahmad K, et al. Hyperfractionated radiation therapy and bis-chloroethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72 Gy on 1.2 BID fractions: report of the RTOG protocol 8302. Int J Radiat Oncol Biol Phys 1993;25:193-207.
43. Brenner DJ. The linear-quadratic model is an appropriate methodology for determining iso-effective doses at large dose per fraction. Semin Radiat Oncol 2008;18:234-9.
44. Turesson I, Notter G. Skin reaction as a biological parameter for prospective studies of different dose schedules with the CRE formula. Bull Cancer 1976;63:11-26.
45. Bated TD, Peters LJ. Dangers of the clinical use of the NSD formula for small fraction numbers. Br J Radiol 1975;48:773.
46. Ellis F. Is NSD-TDF useful to radiotherapy? Int J Radiat Oncol Biol Physics 1985;11:1685-97.
47. Haas-Kogan DA, Yount G, Haas M, Levi D, Kogan SS, Hu L, et al. P53-dependent G1 arrest and p53-independent apoptosis in̄uence on the radiobiologic response of glioblastoma. Int. J. Radiat. Oncol. Biol. Phys 1996;36:95-103.
48. Haas-Kogan DA, Kogan SS, Yount G, Vidair CA, Haas M, Dewey WC, et al. P53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys 1999;43:399-403.
49. Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S. p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol 2010;27:95-101.
50. Lotfi M, Afsharnezhad S, Raziee HR, Ghaffarzadegan K, Sharif S, Shamsara J, et al. Immunohistochemical assessment of MGMT expression and p53 mutation in glioblastoma multiforme. Tumori 2011;97:104-8.
51. Amelio D, Lorentini S, Schwarz M, Amichetti M. Intensity-modulated radiation therapy in newly diagnosed glioblastoma: a systematic review on clinical and technical issues. Radiother Oncol 2010;97:361-9.
52. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987;66:865-74.
53. Earnest F, Kelly PJ, Sheithauer BW, Kall BA, Cascino TL, Ehman RL, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988;166:823-7.
54. Agbi CB, Bernstein M, Laperriere N, Leung P, Lumley M. Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants. Int J Radiat Oncol Biol Phys 1992;23:321-6.
55. Nakagawa K, Aoki Y, Fujimaki T, Tago M, Terahara A, Karasawa K, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998;40:1141-9.
56. Gutin PH, Prados MD, Phillips TL, Wara WM, Larson DA, Leibel SA, et al. External irradiation followed by an interstitial high activity iodine 0125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 1991;21:601-6.
57. Fitzek MM, Thornton AF, Rabinov JD, Lev MH, Pardo FS, Munzenrider JE, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 1999;91:251-60.
58. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf
59. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006;12:4738-46.